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Donor cell chimerism permitted by 
immunosuppressive drugs: a new 
view of organ transplantation 
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Massimo Trucco and Camillo Ricordi 
One line of thought in organ transplantation feels that immunosuppressive 
drugs can lead to tolerance induction by allowing a previously unrecognized 
common mechanism of cell migration and microchimerism to occur, 
persist, and in some cases, become drug independent. It has been recognized 
that there is a spectrum of susceptibility of different organs to cellular 
rejection and that the variable ability of these organs to induce donor-
specific nonreactivity reflects their comparative content of migratory 
leukocytes. Here, Thomas Starzl and colleagues discuss how many of the 
enigmas of transplantation immunology can be explained by this chimerism. 
The prevention of organ rejection by various immuno-
suppressive agents has been described increasingly in 
terms of the molecular site of disruption of the allo-
activated T-cell response1•2• Recent evidence, however, 
suggests that the control of rejection and, ultimately, 
graft acceptance depend on a permissive effect of these 
drugs on a mutual host-graft leukocyte migration 
that leads in successful cases to mixed, long-term 
microchimerism in the recipient as well as the trans-
plant3 (Fig. 1). 
An empiric drug regimen 
Observations compatible with this concept were 
reported in 1963 when combination therapy with aza-
thioprine and prednisone was introduced for kidney 
transplantation4 • There is a characteristic cycle of renal 
graft rejection in the first few days or weeks that can 
be reversed with steroids. The ability to reduce (Fig. 2), 
or sometimes even to stop, treatment was thereafter 
confirmed in cases of transplantation of the liver, heart 
and other organs. 
The reproducibility of these events led to the funda-
mental therapeutic dogma that forms the basis of 
whole organ transplantation surgery. It calls for daily 
baseline treatment with a maintenance drug or drugs 
(originally azathioprine) plus trial and error interven-
tion with the highly dose-manouverable adrenal corti-
cal steroids, along with anti-lymphoid agents to what-
ever level is required to maintain stable graft function. 
Throughout the years, this policy framework has 
accommodated increasingly potent new agents with 
variable sites of action (Table 1). 
The chimeric host and graft 
Under the regimes described above it became evident 
that something, not drug specific, appeared to have 
changed in either the graft, the recipient or both. But 
what? 
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Fig. 1. The mutual engagement of migratory immunocytes from the graft and the recipient following organ transplantation under potent 
pharmacological immunosuppression. GVH: graft versus host; HVG: host versus graft. 
Kidney transplantation 
A clue was found when tuberculin, coccidiodin and 
other delayed hypersensitivity skin test reactions in live 
kidney donors were shown to be transferred to the pre-
viously negative recipients, along with the transplanted 
kidneys5. Speculation that this was 'caused by adoptive 
transfer of donor cellular immunity by leukocytes in 
the renal graft vasculature and hilar lymphoid tissue'6, 
was undermined by the perception of the kidney as a 
leukocyte poor organ. Several years would pass before 
it became accepted that tissues and organs contained 
immunologically significant 'passenger leukocytes'7. It 
was subsequently demonstrated that these included the 
distinctive bone marrow-derived dendritic cellss in-
itially defined in 1973 by Steinman and Cohn9,lo that 
were correlated with organ immunogenicityll. 
Confirmation that cell migration had occurred came 
when five of the original kidney transplant patients 
were reexamined in 199212, after nearly 30 years. 
Their still functioning HLA mismatched kidneys were 
studied; HLA allele or Y chromosome analysis using 
cytochemical or polymerase chain reaction (PCR) tech-
niques on biopsies of all five of the allografts showed 
that the interstitial leukocyte population was largely 
made up of recipient cells while the nephrons remained 
donor. More importantly, donor cells that appeared to 
be dendritic leukocytes were also found in the skin and 
lymph nodes of each of the five recipients. The pres-
ence of donor DNA in these locations was confirmed 
by PCR; blood chimerism was also detected in two of 
the five. For four patients the volunteer donors were 
still alive and all four showed donor-specific nonreac-
tivity by mixed lymphocyte reactivity (MLR) and/or 
cell-mediated lymphocytotoxicity (CML) testing 12• 
Liver and other organs 
Another under-appreciated clue to cell migration was 
the demonstration in 1969 that the Kupffer cells and 
other interstitial monocytes and macrophages of a trans-
planted human liver were replaced within 100 days by 
cells of the recipient phenotype13• The resulting compos-
ite (chimeric) structure was assumed to be a special fea-
ture of the hepatic graft. However, it was shown in 
1991 that the transplanted intestine underwent a similar 
transformation in rats14 and humans15. It was therefore 
suspected that this process must be generic to all suc-
cessfully engrafted organs; and was soon confirmed 
(reviewed in Ref. 16). The hematolymphoid nature of 
the responsible cell traffic was evident from the periop-
erative burst of donor mononuclear cells in the peripher-
al blood of human liver-intestinal or intestinal 
recipients15,17. The question of the fate of the donor cells 
departing the human intestinal graft went unanswered, 
but it was promptly shown by Murase et al. in rats that 
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Fig. 2. The characteristic cycle of immunological confrontation and recovery after organ transplantation (in ,this case ~idneyF that has dictated the 
use of immunosuppressive drugs for the last 30 years. Following a period of good postoperatIVe renal functIOn, relectlon 2-112 w~eks after trans-
plantation (Tx) was correlated with a fall in creatinine clearance (Ccr), a rise m blood urea mtrogen (BUN) and an mcrease m Clrculatmg whIte 
blood cells (WBC). The adverse findings were reversed with prednisone, which was later discontinued along with a reduction of mamtenance aza-
thioprine. The kidney allograft in this 23 year old man functioned continuously from April 1963 until death from a myocardial infarction in 
1990. (Adapted from Starzl, T.E., Experience In Renal Transplantation, W.B. Saunders Company, Philadelphia, PA, 1964, p. 167.) 
these cells from the intestine did not perish out to at 
least two months and in certain strain combinations 
uniformly caused graft versus host disease (GVHD)18,19. 
As with kidney transplantation, long-term chim-
erism after liver replacement was proved in 1992 by 
studying 25 patients who had received livers 2 to 22 
years previously under treatment with azathioprine or 
cyclosporine-based immunosuppression3,16,20,21. Most 
were clinically well and fully immunocompetent as 
shown by conventional in vitro testing. Using the same 
cytochemical or peR techniques as for the long surviv-
ing kidney recipients, donor cell chimerism was found 
in all 25 patients in locations that included skin, lymph 
nodes, heart, lungs, spleen, intestine, kidneys, bone 
marrow and thymus. Chimeric cells were found in 
larger numbers at any given site than in the contempor-
aneously studied long surviving kidney recipients. The 
heavy endowment of the liver with potentially mi-
gratory white cells was postulated to be the basis for the 
'hepatic tolerogenicity' that allows the liver to induce 
its own acceptance more readily than other trans-
planted organs (in some experimental models without 
immunosuppression)22-24. This is also postulated to be 
the basis by which donor livers shield concomitantly 
transplanted organs from rejection24,25, and even to 
resist the attack of preformed antibodies26 • 
Cell augmentation with donor bone marrow, splenocytes 
or blood 
Thus, the hypothesis is that the heavy content (and 
perhaps the specific lineage) of migratory cells in the 
liver accounts for the immunological advantages of the 
hepatic graft. A corollary, therefore, is that organs such 
as the kidney and heart with a smaller leukocyte com-
ponent must have similar inherent, although less tolero-
genic, potential. The frequently advanced strategy of 
intravenously infusing donor bone marrow, donor 
blood (donor specific transfusion) or other hematolym-
phoid cells at the same time, or shortly after, transplan-
tation of whole organs27- 31 is merely an augmentation 
of the normal post-transplant cell migration. To mimic 
the natural process, these cells should be given periop-
erativeiy, not in advance or afterwards as usually has 
been done with the so-called Monaco model. 
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Table 1. Central therapeutic dogma 
Strategy 











2) Secondary adjustments with steroids or antilymphoid agents 
3) Case to case trial (and potential error) of weaning 
Graft and host chimerism appears to be an invari-
able finding after (and we believe an essential con-
dition for) successful organ transplantation. Indeed, it 
may become independent of drug therapy but there is 
no way presently to know if and when the time has 
arrived. In a recently reported group of 44 human liver 
recipients who had survived between 11 and 23 years, 
there were 6 (14%) who had stopped all immunosup-
pression one to 11 years postoperatively with sub-
sequent, clinically stable, drug-free intervals of between 
5 and 13 years16; another 15 with shorter follow-up 
periods are stable without drugs. The most extreme 
example of early successful drug discontinuance was 
after two months. A trial of drug weaning has been 
started in liver recipients with a rejection-free course 
exceeding five years. Liver graft rejection (if it occurs) 
can be so effectively treated with FK506 (Ref. 32) 
that the benefits of coming off drugs appear to us to 
outweigh the risks in selected patients. 
The relative safety of drug stoppage in liver versus 
kidney recipients was shown long ago in dogs treated 
with azathioprine for only four postoperative months22• 
Canine liver recipients rarely rejected their grafts subse-
quently, whereas the incidence of fatal rejection of kid-
ney allografts was 75% (Ref. 33). The higher risk from 
rejection after stopping immunosuppression in human 
kidney compared to liver recipients is well known. 
Nevertheless, a drug free state after renal allotransplan-
tation has been accomplished more frequently than is 
generally known, particularly with the use of living 
related donors. Of the 17 kidney allografts in the world 
that are still continuously functioning from before 
March 1964, 10 are carried by the original Colorado 
patients in whom azathioprine-prednisone therapy was 
developed34,35. Four of these 10 recipients (all with liv-
ing, related kidneys) have been off drug treatment for 6 
months, 12, 27 and 28 years. Strober et al.l6 have re-
ported successful drug weaning in cadaver kidney recipi-
ents pretreated with total lymphoid irradiation and a 
short course of conventional postoperative drug therapy. 
Functional consequences of miccochimerism: cause and 
effect 
Although the chimeric donor cells appear sparse in 
recipient tissues, even after liver transplantation, their 
widespread distribution suggests that the cumulative 
load must be substantial. 
Metabolic effects 
The striking ability of the minority population of 
chimeric cells to have widespread effects on body 
metabolism was shown in patients treated with liver 
transplantation for the pancellular enzyme deficiencies 
of Type 4 glycogen storage disease (branching enzyme 
deficiency with amylopectin storage) and Gaucher's 
disease (P-glucocerebrosidase deficiency and storage 
of glucocerebroside)21. Although these disorders were 
previously thought to be correctable only with bone 
marrow transplantation, there was dramatic resorption 
of both kinds of storage material from host extra-
hepatic tissues over periods of two to eight years after 
liver replacement. In these patients, donor cells could 
be demonstrated in the heart, lymph nodes, bone mar-
row, intestine, skin and elsewhere. There is apparently 
a coculture effect in these tissues of a small number of 
chimeric donor cells on the contiguous overwhelming 
numbers of enzyme-deficient recipient cells. This raises 
important questions about the potential cell-to-cell 
effect of other molecules directly involved in immuno-
logical processes, including tolerance induction. 
The immunological interface 
Much needs to be learned about how the chimeric 
donor cells, which resemble dendritic cells, are per-
petuated for as long as three decades post-transplan-
tation. At the outset, dendritic cells could be spawned 
by small numbers of progenitor cells in the residual 
blood or interstitium of the transplanted organ; such 
precursors have been grown from mouse blood, bone 
marrow, or whole organs using GM-CSF enriched 
media37• More likely, the tissue leukocytes in the organ 
have not reached terminal differentiation as previously 
assumed, but are capable of immediate migration and 
cell division. Whatever the explanation of the early 
events, subsequent survival and renewal of these cells 
must depend upon chronic mutual stimulation of the 
donor and recipient cell populations. Bandeira et al. 38 
have emphasized that tolerance in this context shares 
many of the cellular characteristics associated with 
immunity. As to their immunological function, there is 
no direct way to test how this small population of donor 
dendritic and other cells could have an impact far 
exceeding its numbers. 
Changed host and graft interactions 
In spite of these limitations of measurement, it can 
be inferred that the coexisting immunocyte populations 
in successful cases come to regard each other in a 
revised light. The evidence on one hand is the fading 
of the threat of clinical rejection concomitant with 
development of donor specific reactivity in spite of 
lightened treatment, and on the other, the waning 
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spectre of GVHD. Appreciation of this latter change 
has been the crucial factor permitting the successful 
engraftment of leukocyte-rich organs such as the liver, 
intestine, both together, or all of the intra-abdominal 
organs (multivisceral transplantation). The secrets were 
not to deplete the immunological component of the 
graft and not to alter the recipient reactivity with 
pretreatment39, and to accept that mixed allogeneic 
chimerism was a natural consequence of organ trans-
plantation under immunosuppression. No leap of faith 
was then required to equate the GVHD resistance seen 
in the liver, intestinal, or multivisceral recipient to the 
GVHD resistance described years ago in mouse bone 
marrow transplant models of mixed chimerism by 
Slavin and Strober28 and Ildstad and Sachs29. 
Impact on tissue matching 
In both the directions of host versus graft (HVG) 
and graft versus host (GVH), cellular interactions 
resulting in 'mutual natural immunosuppression' are 
envisioned as occurring on a sliding scale with each 
further level of histoincompatibility (Fig. 3). Under the 
protective umbrella of modern day immunosup-
pression, the acute storm can be weathered long enough 
to allow the changes caused by the cell engraftment to 
occur and a rapprochement to be reached. The antici-
pated histocompatibility influence on both rejection 
and the severity of GVHD are then expected to 
dwindle and this may explain the poor correlation of 
HLA matching with outcome in whole organ cadaveric 
transplantation. 
Migratory eel/load and pace of donor-recipient change 
The rapidity and/or ease of this transformation is 
undoubtedly increased by a heavy load of the tolero-
genic leukocytes migrating naturally from a trans-
planted organ (re: liver transplantation) or by a supplemen-
tal infusion of bone marrow or blood (see earlier sec-
tion). However, the mutual drug-free 'take' of the 
leukocytes cannot be made time independent by cell 
dosage only. The rapidly evolving drug free donor 
specific tolerance that comes with multilineage, mixed 
allogeneic or xenogeneic bone marrow chimerism in 
small rodents28,29,4o has created an unrealistic expec-
tation that the same thing applies for outbred major 
histocompatibility complex (MHC) mismatched large 
animals and humans. 
Clinical trials with bone marrow supplementation 
for liver41 and kidney transplantation3! have shown 
that the guidelines for drug weaning under the circum-
stances of cell augmentation will be similar to those 
already established after conventional liver transplan-
tation. Some patients may not need drug treatment 
after a few weeks or months to ensure stability of the 
mixed chimerism, some may require years and a few 
may never reach this state without risking rejection, 
GVHD or both. 
The critical dendritic cell 
Generation of an immune response leading, under 
normal circumstances, to graft destruction and/or 
GVHD requires effective antigen presentation and 
recognition in its initial phase followed by a second co-
stimulatory signal and the response of T cells to the 
combined signal42. Both of these signals are normally 
delivered to T cells by professional antigen-presenting 
cells (APC). Of these APCs, the dendritic cell (the most 
prominent chimeric cell by morphological criteria) is 
critical because it can modify the expression of cell 
interaction, MHC, and adhesion molecules - all of 
which determine how antigen signals are heeded by T 
cells43. Thus the dendritic leukocyte is the prime candi-
date in this tolerogenicity scenario, even though other 
lineages may also be essential for the successful out-
come of such an immunological transaction. 
Relation of cell migration to tolerance 
Recent reviews have emphasized the inadequacy of 
thymic clonal deletion to explain acquired transplan-
tation tolerance and have focused on post-thymic 
mechanisms that include peripheral clonal deletion and 
anergy44. 
Compatibility with other hypotheses 
Although a discussion of the meaning of tolerance is 
beyond our intention, we note here that all of the 
hypotheses to explain 'Clonal silencing' will be enriched 
by the discovery of the enduring intimacy of the graft 
and host immunological systems that is inherent with 
chimerism. The evidence of vitality and turnover of 
donor leukocytes in recipient tissues as long as three 
decades post-transplantation is particularly supportive 
of the opinions of Coutinh038,45 and Cohen46 . They 
have defined acquired tolerance as a high (not anergic) 
level of sustained immune activity in networks 
interacting in a more complex fashion than the 
idiotype systems originally postulated by Jerne47. 
Suppressor and/or veto cells could be epiphenomena of 
this kind of activity; perhaps it is not too much to ask 
if these are altered dendritic cells rather than T 
lymphocytes, as commonly assumed. 
Throughout the years, the testing of every genuinely 
potent immunosuppressant has been followed by ex-
cited claims of tolerance induction. Now a common 
mechanism appears to be cell migration and 
chimerism, no matter what the site of the drug action. 
The very simplicity of these events in organ recipients 
cloaked their existence and delayed their discovery. 
With this understanding, it should be possible using 
drugs with known sites of action to ask more specific 
questions about the relation of drug-induced tolerance 
to the kind of acquired tolerance originally produced 
with intrauterine or neonatal splenocyte inoculation in 
mice by Billingham, Brent and Medawar48. 
For example, it has been proposed from obser-
vations in drug free models of tolerance induction that 
T-cell receptor (TCR) occupancy leads to production 
of negative regulators of IL-2 production (anergy pro-
teins)42,49. According to this hypothesis, during the 
course of a normal T-cell response (to alloantigens) 
these negative regulators of IL-2 production have an 
inconsequential effect because they are diluted out by 
vigorous cell replication driven by IL-2. However, 
these negative regulators would accumulate with conse-
quent anergy if clonal expansion were prevented at any 
level: for instance, by the absence of a costimulatory 
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signal in drug-free models42 but also by pharma-
cological interdiction of IL-2 gene transcription 
(cyclosporin and FK506) or administration of a DNA 
synthesis inhibitor (azathioprine, cyclophosphamide 
and numerous others). The use of non T-cell depleting 
monoclonal antibodies, such as those directed against 
the cell surface CD4 antigen or monoclonal antibodies 
against adhesion molecules including ICAM-l and 
LFA-150 can also be envisaged. 
Parking experiments revisited 
In the two-stage parking models ll ,40, stage 1 consists 
of the induction with drug or irradiation treatment of 
permanent whole organ acceptance, for which the word 
tolerance usually is studiously avoided, even though it 
would be an apposite term in the context of the cell 
migration hypothesis. Once the graft's passenger 
leukocytes are replaced by migratory cells from the 
host, the composite organ that is excised and retrans-
planted at the second stage is rejected by naive animals 
of the donor, but not the recipient strain. However, 
these results can be accomplished only when immuno-
logically 'easy'rat strain combinations are usedll ,40 or 
with perfect MHC matching in larger animals51 • Even 
then, the outcome tends to be variable. 
The parking model has been a useful research tool. 
However, results from parking experiments cannot be 
freely extrapolated to a discussion of the cell migration 
concept because neither the host immunocytes (includ-
ing those that home to the parked organ) nor the 
donor leukocytes seeded ubiquitously in the recipient 
remain the same. Throughout this discourse and else-
where3,12,16,20,21, we have emphasized that the non-
responsiveness induced after cell migration involves 
GVH as well as host versus graft (HVG) reactions. The 
reciprocal educational process of donor and recipient 
leukocytes and its perpetuation resembles in either 
direction the 'infectious' transplantation tolerance that 
can be passed on to naive lymphocytes and be self sus-
taining in some circumstances (see H. Waldmann and 
S. Cobbold, this issue, pp. 247-251). In fully successful 
cases, the mini-immune system of the graft is incor-
porated into the existing recipient immunological net-
work, compatible with the hypothesis of Coutinh045• 
Incompleteness of this assimilation on the HVG limb 
(Fig. 1) is monitored by evidence of rejection, which 
has been the sole measurable end-point of all parking 
experiments. 
Assimilation on the GVH limb also is ordinarily 
silent, but it can be unmasked with transplantation 
experiments using the LEW to BN strain combination 
that is inherently GVHD proneI8,19. The experiments 
consisted of simulating with a bone marrow infusion 
the natural cell migration that occurs following whole 
organ transplantation; then or later the migratory pass-
enger leukocyte load brought in with a contempor-
aneous or delayed liver or heart allograft was added 
(Demetris, A.]. et al., submitted). In these rat exper-
iments, liver transplantation plus donor strain bone 
marrow did not cause GVHD when both engraftments 
were done simultaneously under immunosuppression. 
However, when chimerism was induced with prelimi-
nary bone marrow transplantation followed by a 28 
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Fig. 3. The donor-recipient leukocyte interaction shown in Fig. 1 is a 
buffer against rejection on one hand and GVHD on the other. Veto and 
suppressor cells are postulated to be the result of the interaction. Rx: 
iatrogenic immunosuppression. 
day course of FK506, subsequent liver transplantation 
after a drug free interval of 18 days invariably caused 
lethal GVHD. 
The outcome with the delayed hepatic transplan-
tation resembled that of a parent to offspring Fl hybrid 
experiment in that the liver including its virgin 
migratory cells was seen as self by the altered host 
immune system, but not having gone through the 
process of modification, the hepatic passenger leuko-
cytes reciprocated by rejecting the defenseless recipient. 
In contrast, heterotopic hearts transplanted under the 
same circumstances of prior bone marrow preparation 
were accepted without causing clinical GVHD, presum-
ably reflecting the smaller supply of cardiac passenger 
leukocytes. 
Unstable mixed chimerism 
Because it inter-relates tolerance, rejection and 
GVHD, the cell migration concept creates a seamless 
single world for transplantation of bone marrow and 
of whole organs. Far from involving different mech-
anisms, we believe that these two seemingly disparate 
fields merely reflect contrasting treatment dogmas. For 
bone marrow transplantation, the treatment strategy 
of recipient cytoablation eliminates mutual immuno-
cyte engagement and thus necessitates heavy reliance 
on HLA matching to prevent GVHD. The treatment 
for solid organ transplantation encourages, or at least 
permits, mutual cell engagement, thereby liberating the 
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patient from the restrictions of HLA matching and an 
overwhelming threat of GVHD. 
Failure of clinical organ transplantation implies the 
inability to achieve mixed allogeneic chimerism despite 
the best available immunosuppression, most commonly 
because of an imbalance leading to rejection. However, 
because an incipient GVH reaction is a necessary con-
dition for success (this is our fundamental premise), 
clinical GVHD is a theoretical possibility after every 
transplantation, although the threat varies from organ 
to organ. We now know that about 5% of all liver recipi-
ents go through a bout of clinical GVHD that in the 
past usually was attributed to an allergic skin reaction16• 
Although the complications of GVHD usually can 
be managed with an increase (most commonly) or 
decrease of immunosuppression, reports of a fatal 
outcome are not uncommon. In one case, the novel 
strategy of reinfusing a patient's stored bone marrow 
dramatically reduced the degree of chimerism and con-
trolled life threatening GVHD that had developed six 
weeks after combined liver and bone marrow trans-
plantation41 • It is not known how the autologous naive 
cells that had been in storage differed from the 
immunocytes in the patient that had become defense-
less against attack after cohabiting with chimeric 
donor cells but the clinical case appeared to be a 'mir-
ror image' of the staged bone marrow-liver transplan-
tation in rats described in the preceding section in 
which GVHD was switched on, not off. This thera-
peutic 'rescue' on the patient was reminiscent of a toler-
ance breaking experiment by infusion of a naive recipi-
ent strain of immunocytes that was described in 1956 
by Billingham, Brent and Medawar48. 
Guidance was generously and frequently provided by 
Robert A. Good (St Petersburg), G.J.V. Nossal (Melbourne), 
Ralph Steinman (New York), and Leslie Brent (London). 
During the preparation of the manuscript Nossal emphasized 
the similarity of our clinical observations to the phenomenon 
of 'exhaustive clonal differentiation' studied in the nontrans-
plant mouse model52• Aided by project grant No DK29961 
from the National Institutes of Health, Bethesda, Maryland. 
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